The filing record for Genvor Inc. documents material-event disclosures for an OTC biotechnology issuer focused on peptide technology. Recent 8-K reporting covers corporate events, executive or commercial updates, registered office information and public-company disclosure obligations.
Genvor's SEC materials provide formal context for its capital structure, governance and material announcements while company news supplies most of the operating detail. The filings record supports the company's public reporting profile around biotechnology research, partnerships and commercialization activity.
Genvor Inc. (GNVR) filed a Form 10-K/A correcting a typographical error in its independent auditor's signature date and restating select disclosure items from its 2023 Annual Report. The filing discloses that for the year ended September 30, 2023 the Company recognized a net loss of $1,707,481, had no revenues, and used $871,734 in operating cash, and that these conditions raise substantial doubt about the Companys ability to continue as a going concern. The filing details multiple debt instruments, including a note maturing March 13, 2024 with 10% interest convertible into 134,000 common shares, conversions of $989,000 principal and $146,946 interest into 2,316,147 common shares, and other conversions and warrant issuances. It reports extensive share issuances and transfers across Series A and B preferred and common stock, related-party transactions and settlement terms, net operating loss carryforwards of $2,497,000 and $2,133,000 (available through 2043), deferred tax asset balances, and various contingent liabilities, fees, and subsequent small equity issuances. The filing also references a merger with Old Genvor and settlement payments tied to cancellation of preferred shares.